...
首页> 外文期刊>Toxicology mechanisms and methods >Detection of opioids in umbilical cord lysates: an antibody-based rapid screening approach
【24h】

Detection of opioids in umbilical cord lysates: an antibody-based rapid screening approach

机译:脐带裂解物中阿片类药物的检测:基于抗体的快速筛选方法

获取原文
获取原文并翻译 | 示例
           

摘要

In pregnancy, opioids may be used medically and also misused. We hypothesized that the umbilical cord (UC) could be a good screening tool for determining opioid exposure and improving medical care. One hundred and one UC, each with 50 associated ICD9/ICD10 codes were used. Using predictive pharmacokinetic analysis we determined that opioids could be detected since last ingestion prior to birth. The UC were lysed and screened using ELISA detecting multiple opioids and their metabolites. Statistical comparisons to obstetric and neonatal outcomes were performed. Although the commercial ELISA was less sensitive in UC than blood or urine, there was perfect method selectivity as compared to a subset of cords designated positive or negative by clinical diagnostics, so our results are accurate and reliable. Absolute quantitation was not possible because the antibody cross reacts with multiple compounds, but 'low' or 'high' levels of exposure were assigned. Prevalence of opioids was 11%, which reduced to 7% when cesarean-section births were eliminated. For non-cesarean-section infants adjusted for preterm birth, advanced maternal age and smoking (independent risk factors), opioids were significantly associated with intra-uterine growth restriction (p = 0.017) and admission to neonatal intensive care (p = 0.002). UC can be collected noninvasively and rapidly providing a reliable tools for semi-quantitative opioid screening using ELISA. Moreover, as UC are usually discarded collection presents few technical or safety concerns for staff or patients. Further development of this methodology may provide a rapid, noninvasive clinical screening tool to identify NAS and/or opioid use in late pregnancy.
机译:在妊娠中,阿片类药物可以医学和滥用。我们假设脐带(UC)可以是用于确定阿片类药物暴露和改善医疗护理的良好筛查工具。使用一百个UC,每个UC都使用具有50个相关的ICD9 / ICD10代码。使用预测性药代动力学分析,我们确定了自生育前的最后摄取以来可以检测到阿片类药物。使用ELISA检测多种阿片类药物及其代谢物,裂解UC并筛选。进行统计学比较和产科和新生儿结果。虽然商业ELISA在UC的敏感性上比血液或尿液较小,但与临床诊断指定阳性或阴性的脐带子集相比,有完美的方法选择性,因此我们的结果是准确可靠的。绝对定量是不可能的,因为抗体交叉与多种化合物反应,但分配了“低”或“高”的暴露水平。阿片类药物的患病率为11%,当消除剖宫产分娩时减少到7%。对于用于早产的非剖宫产患者进行预发育,先进的孕产妇年龄和吸烟(独立风险因素),阿片类药物与子宫内生长限制(P = 0.017)显着相关(P = 0.017)并进入新生儿重症监护(P = 0.002)。可以使用ELISA非侵入地和快速地收集uc,为半定量阿片类筛选提供可靠的工具。此外,随着UC通常被丢弃的收集,员工或患者的少数技术或安全问题。这种方法的进一步发展可以提供快速,无创临床筛查工具,以鉴定妊娠晚期的NAS和/或阿片类药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号